TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05040425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zi-Yin-Liang-Ge-San
Description: Zi-Yin-Liang-Ge-San is composed of five herb ingredients, namely Rx. Scutellariae (Huang Qin), Rx. Glycyrrhizae (Gan Cao), Hb. Dendrobii (Shi Hu), Rx. Ophiopogonis (Mai Men Dong), and Hb. Menthae Haplocalycis (Bo He). It is orally administrated trice daily from the first day to the end of RT in the treatment group, aiming to prevent and manage the OM. ZYLGS is manufactured as a concentrated herbal extract, constituted 4 g per packet, and origin from pharmaceutical companies in Taiwan with good manufacturing practice (GMP).
Study: NCT05774561

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arm A - Diagnostic test: HPV detection in liquid biopsies
Description: Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arm B - Diagnostic test: HPV detection in liquid biopsies
Description: Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians.
Study: NCT03277495

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief behavioral counseling
Description: Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief behavioral counseling
Description: Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention
Study: NCT04647526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Lu-177]-PNT2002
Description: Participants randomized to Arm A will receive 6.8 GBq (±10%) of \[Lu-177\]-PNT2002 every 8 weeks for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide (160 mg orally qd)
Study: NCT05767255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine - Insulin Aspart
Description: The insulin dose of the basal group will be adjusted according to the blood glucose reports presented by the patients.
Study: NCT06647589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: participants will then receive ACT-based individual therapy weekly for eight weeks.
Study: NCT05043649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camsirubicin
Description: The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
Study: NCT04837365

Intervention type: OTHER
Group type: OTHER
Intervention: Three dimensional gait analysis with eyetracking
Description: An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.

Intervention type: OTHER
Group type: OTHER
Intervention: Three dimensional gait analysis with eyetracking
Description: An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.
Study: NCT05309265

Intervention type: OTHER
Group type: OTHER
Intervention: Multidisciplinary vocational rehabilitation intervention
Description: * Information aims to provide tailored information concerning the work law protection (this support is already provided for all patients, regardless the type of disease, and also for citizens);~* Occupational therapy aims to facilitate the reintegration in the previous workplace through the development of a rehabilitation intervention to overcome work difficulties in agreement with employee, employer and occupational physician,~* Social support aims to find new job opportunities (for those who have lost the employment due to the disease) through the giving of support in job search, curriculum preparation, skill analysis, professional retraining and education.
Study: NCT05503108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking diet program
Description: Fasting mimicking diet by L-Nutra, a 4-day low caloric, low protein, vegetarian diet 3 days prior to and the day of neoadjuvant chemotherapy administration. The FMD will take place every 4 weeks, thus in total 5 times (2x during ddAC, 3x during Paclitaxel) during the neoadjuvant chemotherapy.
Study: NCT06066385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small bites technique
Description: Closure of the fascia after midline laparotomy using a slowly resorbalbe 2.0 suture, with 0.5 cm bites, and 0.5 cm between the stitches, at least resulting in a 1:4 wound length:suture length ratio.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional large bites closure
Description: Closure of a midline laparotomy using a slowy resorbable thick suture (e.g. PDS loop) with large bites and large steps (\>= 1 cm).
Study: NCT05664191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Infusion at 0.1 µg/kg/min at day 1 and day 8

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose 5%, solution for injection ECOFLAC at day 1 and day 8
Study: NCT05325177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Ibuprofen
Description: (10-5-5 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Ibuprofen
Description: (20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
Study: NCT06216132

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BIOPIN-6 Active Implant with Naltrexone
Description: An extended release formulation of naltrexone implanted in the subcutaneous space.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BIOPIN-6 Placebo Implant
Description: The placebo will be an implant consisting of the poly-d-l Lactic Acid and polycaprolactone contained in BIOPIN 6 without naltrexone.
Study: NCT05484206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection.
Study: NCT05867446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pecha kucha
Description: pecha kucha training
Study: NCT06193876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Petitgrain and ylang-ylang essential oil
Description: Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Petitgrain and ylang-ylang essential oil
Description: Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Petitgrain and ylang-ylang essential oil
Description: Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.
Study: NCT05734794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
Study: NCT04731649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together Plus (FTT +)
Description: FTT + consists of three online intervention sessions of approximately 60-90 minutes each, that cover content from nine modules designed to teach parents effective communication skills, build parent-adolescent relationships, help parents develop successful monitoring strategies, and teach adolescents assertiveness, refusal skills, and how to use a condom correctly and every time.
Study: NCT05122416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (S)
Description: A FibroScan examination with the Exploratory S probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (S)
Description: A FibroScan examination with the Exploratory S probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (M)
Description: A FibroScan examination with the Optimized M probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (M)
Description: A FibroScan examination with the Optimized M probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (M)
Description: A FibroScan examination with the Optimized M probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (XL)
Description: A FibroScan examination with the Exploratory XL probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (XL)
Description: A FibroScan examination with the Exploratory XL probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (XL)
Description: A FibroScan examination with the Exploratory XL probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (Standard M)
Description: A FibroScan examination with the Standard M probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (Standard M)
Description: A FibroScan examination with the Standard M probe.
Study: NCT05484206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection.
Study: NCT05473156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP203
Description: Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D\[s\]).~Participants will be administered by intravenous (IV) infusion, every week (Q1W \[± 1days\]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W \[± 3 days\]) for all the following doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP203
Description: The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP203
Description: The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP203
Description: The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.
Study: NCT06338020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive variable-resistance training
Description: The training was conducted thrice weekly for eight successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: The program encompassed the standard exercises for survivors of ALL (flexibility, graduated active strengthening, and conditioning exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
Study: NCT05122416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (Standard M)
Description: A FibroScan examination with the Standard M probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (Standard M)
Description: A FibroScan examination with the Standard M probe.
Study: NCT06547905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostomy Leakage Detection System
Description: A system that is used to detect ostomy leaks
Study: NCT06039787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: single bout of moderate intensity continuous training (MICT)
Description: the MICT consists of 60 min continuous cycling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: single bout of High Intensity Interval Training (HIIT)
Description: HIIT consists of 10-min warm-up at the power output corresponding to 50% peak power output (PPO), 4 x 4-min intervals at a power output corresponding to 75% PPO with a 4-min active resting period at 30% PPO to recover

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: waiting control
Description: sitting in a waiting room for 60 min
Study: NCT04728087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACCEL® Absorbable Hemostat Powder
Description: Up to 2 bellows (10 grams nominal) of ACCEL®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01)
Description: Up to 12.5 cm x 8.0 cm of Gelfoam® or SURGIFOAM® .
Study: NCT05078710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: 160mg once a week for 24 weeks
Study: NCT06479044

Intervention type: DIAGNOSTIC_TEST
Intervention: Herrmann Brain Model
Description: The test comprises 120 multiple-choice items on academic, daily, and professional scenarios

Intervention type: DIAGNOSTIC_TEST
Intervention: Herrmann Brain Model
Description: The test comprises 120 multiple-choice items on academic, daily, and professional scenarios

Intervention type: DIAGNOSTIC_TEST
Intervention: Herrmann Brain Model
Description: The test comprises 120 multiple-choice items on academic, daily, and professional scenarios

Intervention type: DIAGNOSTIC_TEST
Intervention: Herrmann Brain Model
Description: The test comprises 120 multiple-choice items on academic, daily, and professional scenarios
Study: NCT05122416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (Standard M)
Description: A FibroScan examination with the Standard M probe.
Study: NCT06218017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen fist
Description: Patients in the two study group first underwent a 10-minute session of high-flow nasal oxygen (50 L/min) followed by the utilization of the standard low-flow nasal oxygen (4 L/min) or underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal oxygen later
Description: Patient in this group underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min)
Study: NCT06651788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethyl Chloride
Description: Topical anesthetic that rapidly cools the skin and underlying tissues

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cold Saline Spray
Description: placebo application of cold saline spray
Study: NCT06651697

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy with full bladder or empty bladder protocols

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy with full bladder or empty bladder protocols
Study: NCT04298567

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto,Bay 59-7939)
Description: Rivaroxaban (2.5 mg \[BID\])

Intervention type: DRUG
Intervention: Acetylsalicylic acid(ASA)
Description: ASA (75mg \[QD\]; dose according to local label.
Study: NCT06491121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology supported High Intensity Training
Description: patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home, supported by a smartphone application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Training
Description: patients will perform a 12-week MIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory continuous load, general resistance and core muscle training, all at moderate intensity. Phase 2 is a similar 12-week MIT program at home with an exercise program on paper.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Training
Description: patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home with an exercise program on paper.
Study: NCT06657807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online CBT
Description: Online CBT targeting anxiety in pediatric asthma
Study: NCT06606366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample taken for the liquid biopsy
Description: 36 mL will be taken for the study.
Study: NCT06667921

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound will be used to measure the hyomental distance in neutral position (HMDRn), hyomental distance in extended position (HMDRe), (HMDR) and (DSE).
Study: NCT06670079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy + incentives for therapy session attendance
Description: Prolonged exposure therapy plus incentives for therapy session attendance
Study: NCT06669806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIPS Stent Graft
Description: a covered TIPS stent graft
Study: NCT05809986

Intervention type: OTHER
Intervention: Ofatumumab
Description: There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis

Intervention type: OTHER
Intervention: Ofatumumab
Description: There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
Study: NCT05699837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audio or visual alpha (10Hz) stimulation
Description: Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audio or visual alpha (10Hz) stimulation
Description: Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation
Study: NCT06670066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Talk Birth Control
Description: Let's Talk is an innovative, multi-level intervention addressing adolescents and providers that includes both in-person and online components and is feasible to implement in clinical settings. The three core components are: (1) a printed contraceptive decision aid (CDA) with a QR code linking to the Method Explorer (ME) page on Power to Decide's online birth control website, Bedsider; (2) the Bedsider ME, with information on the full range of contraceptive methods and a personalized method comparison feature; and (3) an online training for providers on Patient-centered Contraceptive Counseling (PCCC), including use of the CDA to support shared decision-making with adolescents.
Study: NCT05646680

Intervention type: PROCEDURE
Group type: OTHER
Intervention: two step adnexectomy
Description: instead of standard resection of salpinx and ovary, they are now separately excised
Study: NCT06678789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Nicotine Dose
Description: Will receive a 5-week supply of 6 mg Zyn pouches. Those who smoke 5-20 cigarettes per day will receive 1 tin per day = 35 tins, whereas those who smoke more will receive 2 tins/day \[70 tins\])

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Nicotine Dose
Description: Will receive a 5-week supply of 3 mg Zyn pouches. Those who smoke 5-20 cigarettes per day will receive 1 tin per day = 35 tins, whereas those who smoke more will receive 2 tins/day \[70 tins\])